Neurocrine Biosciences Data Shows Rapid Improvement in Mild Tardive Dyskinesia with INGREZZA

Event summary

  • Neurocrine Biosciences presented real-world data showing 96% of patients with mild tardive dyskinesia (TD) improved with INGREZZA treatment.
  • 86% of patients saw improvements within four weeks of starting INGREZZA.
  • The study, presented at the American Psychiatric Association 2026 Annual Meeting, involved 90 patients with mild TD.
  • Patients reported improvements in functional status, independence, and ability to work or attend school.
  • The data supports the American Psychiatric Association clinical guidelines for treating mild TD with vesicular monoamine transporter 2 inhibitors.

The big picture

The data underscores the functional impact of even mild TD, a condition often overlooked in treatment decisions. Neurocrine's findings could shift clinical guidelines and reimbursement policies, positioning INGREZZA as a first-line treatment for a broader patient population. The biopharmaceutical industry is increasingly focusing on real-world evidence to demonstrate the value of specialized therapies, particularly in neurological and psychiatric disorders.

What we're watching

Market Expansion
Whether Neurocrine can leverage this data to expand INGREZZA's use in mild TD cases, potentially increasing its market share.
Regulatory Support
How the American Psychiatric Association's endorsement may influence reimbursement and adoption rates for INGREZZA.
Competitive Dynamics
The pace at which competitors develop similar treatments for mild TD, given the growing evidence of its functional impact.